Search PubMed⌕ Search

Biomedical subjects

W C Dick

Publications and source records attributed to W C Dick.

170 records · Page 10Linked to original sources
PubMedDate not supplied

Safety and efficacy of etodolac compared with piroxicam in patients with degenerative joint disease of the knee.

The efficacy and safety of etodolac and piroxicam were compared in a double-blind, randomized, parallel-group outpatient study at four sites. Patients with active osteoarthritis of the knee were assigned to receive etodolac 600 mg/day (57 patients) or piroxicam 20 mg/day (59 patients) for 6 weeks. Efficacy assessments were made at the pretreatment screening, at baseline, and at treatment weeks 2, 4, and 6 for patient and physician global evaluations, night pain, spontaneous pain intensity, weight-bearing pain variables, measures of inflammation, morning stiffness, and knee flexion. An analysis was also done based on each patient's final evaluation, regardless of the week at which it occurred. Safety assessments were made before treatment and at the completion of therapy. A therapeutic response was obtained in both treatment groups by the end of the second week of treatment. At the final evaluation, both groups showed significant improvement (P less than or equal to 0.05) from baseline for most efficacy assessments. The physician's global assessment indicated improvement in the condition of 60% of the etodolac-treated patients and 39% of the piroxicam-treated patients at the final evaluation. There was no significant difference between treatment groups in the number of patient withdrawals due to adverse reactions or in the number of patients reporting side effects. The results of this study indicate that, compared with piroxicam 20 mg/day, etodolac 600 mg/day is effective and well tolerated in the treatment of patients with osteoarthritis.

Adult↗
PubMedDate not supplied

Patient compliance: a novel method of testing non-steroidal antiinflammatory analgesics in rheumatoid arthritis.

Patient compliance has been used as a measure of efficacy of non-steroidal antiinflammatory drugs (NSAID) in the treatment of patients with rheumatoid arthritis. A series of studies on various cohorts of patients using different drugs and different prescribing methods has been conducted. The studies have confirmed the absence of long-term placebo response. Indomethacin emerges as the most effective drug regardless of the mode of prescription, but it is clear from the results that the level of compliance varies with the mode of prescription.

Adult↗
PubMedDate not supplied

Birbeck granules in synovial cells from a patient with rheumatoid arthritis.

Although Langerhans cells were first described as long ago as 1868, it is only relatively recently that details of their structure and function have been ascertained. They appear to be of importance in immune reactions and have been found in mammals in most squamous epithelia, including skin, buccal mucosa, esophagus, and vaginal and rectal mucosa. One of features of these cells is the presence of organelles called Birbeck granules on electron microscopy. We report the presence of cells containing Birbeck granules in the synovium of a patient with rheumatoid arthritis.

Arthritis, Rheumatoid↗
PubMedDate not supplied

Double-blind comparison of etodolac and piroxicam in the treatment of rheumatoid arthritis.

Etodolac is the first of a new class of nonsteroidal anti-inflammatory drugs--the pyranocarboxylic acids--and has potent analgesic and anti-inflammatory properties. Etodolac and piroxicam were compared in the treatment of patients with active rheumatoid arthritis. A total of 118 patients entered this double-blind parallel study and were randomly assigned to receive 200 mg of etodolac twice a day (60 patients) or 20 mg of piroxicam once a day (58 patients) for 12 weeks. After the baseline evaluation, efficacy and tolerability evaluations were made at 2, 4, 6, 8, and 12 weeks. Significant improvement from baseline was noted in both treatment groups in the patient's and physician's global evaluations, in the number of swollen and tender joints, and in the pain intensity scores. Improvement was noted at the first visit (week 2) and continued through week 12. Based on changes in the patient's global evaluation, 56% of the etodolac-treated patients and 47% of the piroxicam-treated patients showed improvement at the final evaluation. Based on changes in the physician's global evaluation, 47% of the etodolac-treated patients and 42% of the piroxicam-treated patients showed improvement at the final evaluation. Eight (13%) patients in the etodolac group and 7 (12%) patients in the piroxicam group withdrew from the study because of adverse events. Most adverse events were mild to moderate; gastrointestinal complaints were the most prevalent adverse events in both treatment groups. No clinically significant changes were seen in laboratory test results or vital signs. These results demonstrate that etodolac is well tolerated and effective in the treatment of the signs and symptoms of rheumatoid arthritis and compares favorably to piroxicam in safety and efficacy.

Adolescent↗